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Appraisal Clinical Practice Guidelines
Parkinson’s disease
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Latest update: 2010. Next update: 2013. Patient group: 
Adults with early, uncomplicated Parkinson’s Disease. 
Intended audience: Clinicians managing patients with 
early Parkinson’s Disease. Additional versions: Nil. 
Expert working group: A task force of 20 experts 
representing the European Federation of Neurological 
Societies (EFNS) and the Movement Disorders Society 
(European Section) were involved in developing these 
guidelines. This guideline development group included 
neurologists and a physiotherapist who represented 15 
European countries: Germany, Italy, Netherlands, United 
Kingdom, Norway, Portugal, Poland, Czech Republic, 
Serbia, Belgium, Sweden, Austria, France, Switzerland and 
Spain. Funded by: European Federation of Neurological 
Societies, Movement Disorders Society (European 
Section), and Competent Network Parkinson. Consultation 
with: Not indicated. Approved by: European Federation 
of Neurological Societies. Location: The guidelines 
are available at the EFNS website: http://www.efns.org/
Guideline-Archive-by-topic.389.0.html
Description: These guidelines present evidence for 
interventions to manage early stage, uncomplicated 
Parkinson’s Disease. This includes pharmacological 
and non-pharmacological interventions. The evidence 
for pharmacological agents to provide neuroprotection 
or disease modiﬁcation, such as a delay in disease 
progression, is discussed, with no trials demonstrating 
unequivocal evidence to date. The guidelines then detail 
many pharmacological interventions (eg, anticholinergics, 
amantadine, MAO-B inhibitors, COMT inhibitors, 
levodopa, and dopamine agents), giving information about 
their mechanism of action and side effects. The evidence 
available for these agents to provide symptomatic treatment 
of motor and non-motor symptoms in early PD is then 
presented, with efﬁcacy compared between different 
types of agents. The evidence for non-pharmacological 
treatment is then provided, with the majority of this related 
to physiotherapy interventions. Evidence is provided for 
several exercise-based interventions including cueing 
strategies, resistance exercise, aerobic training, treadmill 
training, Tai Chi, and Qigong. All 198 cited references are 
listed at the end of the document.
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Bronchiectasis
Bronchiectasis
Latest update: July 2010. Next update: Not indicated. 
Patient group: Adults and children presenting with non-
cystic ﬁbrosis bronchiectasis. These are patients with 
symptoms of persistent or recurrent bronchial sepsis related 
to irreversibly damaged and dilated bronchi. Intended 
audience: Clinicians who manage patients with non-CF 
bronchiectasis. Additional versions: Nil. Expert working 
group: The guideline group consisted of 21 experts, 
including adult physicians, paediatricians, specialist nurses, 
physiotherapists, microbiologists, a general practitioner, 
surgeon, immunologist, radiologist, and a patient 
representative. Funded by: Not indicated. Consultation 
with: External peer reviewers were consulted. Approved 
by: British Thoracic Society. Location: Pasteur MC, Bilton 
D, Hill AT (2010) Guidelines for non-CF bronchiectasis. 
Thorax 65(S1): 1-64. http://www.brit-thoracic.org.uk/
Clinical-Information/Bronchiectasis/Bronchiectasis-
Guideline-(non-CF).aspx
Description: This 64 page document presents evidence-
based clinical practice guidelines on the background, 
potential causes, clinical assessments, investigations, 
and management of adults and children with non-CF 
bronchiectasis. It begins with a 6-page summary of all 
recommendations. The guidelines then provide information 
on the potential underlying causes of bronchiectasis, 
and its associations with other pathologies. The clinical 
presentation in both adults and children is detailed, and 
evidence for diagnostic investigations is provided,such as 
immunological tests, radiological investigations, sputum 
microbiology, and lung function tests. General principles 
of management are indicated, followed by evidence for 
physiotherapy in this condition. This includes interventions 
such as airway clearance techniques, active cycle of 
breathing techniques, manual techniques, positive expiratory 
pressure, autogenic drainage, high frequency chest wall 
oscillation, and exercise. The evidence for the use of airway 
pharmacotherapy such as mucolytics, hyperosmolar agents, 
bronchodilators, inhaled corticosteroids and leukotriene 
receptor antagonists are detailed, followed by evidence 
for management using antibiotics. Recommendations 
are given for assessments needed in patients with acute 
exacerbations in the outpatient and inpatient sector, with 
criteria provided to determine when inpatient treatment 
of an acute exacerbation is required. Finally, evidence for 
surgery, complications and management of the advanced 
disease is provided. All 549 cited references are provided.
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